Recent Updates
Recently added Catalysts
IRWD Neutral Sentiment

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

Wednesday, May 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ironwood Pharmaceuticals has released its financial results for the first quarter of 2025. The report includes various aspects of the company's operations, including leadership, therapeutic focus, and pipeline developments. However, specific financial figures and performance metrics were not detailed in the provided text.
Price reaction · baseline $0.9269 (2025-05-06 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close
-14.6%
day 1 · peak
-24.5%
day 3
-20.8%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)

Full Press Release Details

• Company Company Overview Leadership Open Payments & Transparency
• Science & Medicine Therapeutic Focus Pipeline Product
• Patients Overview
• Responsibility Overview Diversity, Equity & Inclusion Sustainability Safety & Compliance Patients & Research Community Giving
• Careers Working at Ironwood Internships, Co-ops and Fellowships Open Positions
• Investors & Media Contact Us
• Company Overview
• Leadership
• Open Payments & Transparency
• Therapeutic Focus
• Pipeline
• Product
• Overview
• Overview
• Diversity, Equity & Inclusion
• Sustainability
• Safety & Compliance
• Patients & Research
• Community Giving
• Working at Ironwood
• Internships, Co-ops and Fellowships
• Open Positions
• Investors & Media
• Contact Us
ShareAdd on Google
Tags: IRWD Viatris Investor Conferences Healthcare Ironwood Pharmaceuticals Q1 2025 financial results biopharma
Last updated: May 7, 2025

Biotech snapshot

Cash runway
$79M liquidity · $0M/mo burn
Low dilution risk
Lead asset
IW-3718Phase 3
Gastroesophageal Reflux Disease (GERD) →

Catalyst track record

+57%
best trade around IRWD's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for IRWD.

See every catalyst's timing & PoA →